Loading…
← CockpitCompetitor Analysis › 237690.KS ST Pharm Co., Ltd.Open in the cockpit ↗

ST Pharm Co., Ltd.237690.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

Korean pharma/CDMO, part of Dong-A Socio Group, making its own generic drugs plus contract-manufacturing oligonucleotide APIs.

Momentum laggard 18
Mkt cap
$1.11B
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$6.59M
20-day average traded
Fwd P/E
27.8×
forward earnings
ROIC−WACC
+3.8 pp
WACC 6.2%
Hurdle
-18 pp
Req g minus delivered
Next earnings
89 days
15 Feb 2027
Close · KRW₩70,200
1D-1.1%
1W-6.4%
1M-23.9%
3M-34.0%
6M-50.7%
YTD-41.1%
1Y-29.4%
ATR %5.8%
52w lowhigh59.2% off high

What ST Pharm does

Korean pharma/CDMO, part of Dong-A Socio Group, making its own generic drugs plus contract-manufacturing oligonucleotide APIs.

Is paid per batch or under supply agreements by drug developers for making oligonucleotides, short strands of genetic material used as drugs, so revenue depends on when customers' drugs move from trials to commercial supply. Its own branded generics are a smaller, more domestic line.

Products and services

  • Oligonucleotide CDMO (siRNA/antisense APIs)
  • Branded generic pharmaceuticals

Customers

  • Global pharma/biotech clients (CDMO)
  • Domestic pharmacies (own drugs)

Where it sits in the supply chain

  • Pharmaceuticals/CDMO
  • Oligonucleotide API contract…
  • Branded/generic drug sales

What could go right

  • Global RNAi/antisense drug pipeline growth driving CDMO demand

What could go wrong

  • Customer concentration risk (CDMO)
  • Domestic drug-pricing regulation

Moat: narrow (process know-how, customer qualification). One of few global-scale oligonucleotide API manufacturers, a specialized, hard-to-replicate process.

Headquarters: Seoul, South Korea · Founded: 1959 · Employees: 780

ST Pharm at a glance

Size ST Pharm (237690.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.11B, the 224th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩70,200 on 18 Nov 2026.

Performance Over six months the shares fell 50.7%, against -9.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue grew 26.3% over the last twelve months (peer median -1.5%); the operating margin is 17.8% (peer median 4.5%).

Valuation It trades at 27.8× forward earnings against a peer median of 20.2× (5th most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -18 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.8 points above its cost of capital (6.2% WACC).

Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 93237690.KS 53
Six months, rebased to 100: ST Pharm against the median of its 20 peers (local-currency closes).

ST Pharm financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩402B₩332B₩274B₩285B₩249B
Revenue growth—+21%-4%+14%—
Gross profit₩148B₩129B₩90.6B₩107B₩83.3B
EBITDA₩106B₩84.4B₩53.0B₩54.1B₩35.5B
Net income₩60.2B₩55.0B₩34.7B₩19.6B₩18.0B
Free cash flow₩65.7B-₩29.6B₩30.2B-₩41.6B-₩53.0B
Capital expenditure₩31.1B₩47.3B₩83.2B₩43.4B₩60.7B
Total debt₩49.8B₩78.7B₩118B₩192B₩135B

Quarterly statements and history in the cockpit →

ST Pharm competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%VIYASH300119006280VETOCMHCPYCMEDCL4547600812OMER00098919526855NKTR688443BLUEJET600789688321237690.KS6-month return →1-month return →
Up and to the right = strong over both horizons. ST Pharm is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×200×400×VIYASH300119006280CMHC0009891952BLUEJET688321237690.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ST Pharm is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%VIYASH300119VETO002550600812000989BLUEJET600789237690.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. ST Pharm is the large dot.

ST Pharm competitors and peer comparison

How ST Pharm compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ST Pharm against its 20 peers (data as of 18 Nov 2026)
Measure237690.KSPeer medianRank in peer set
1-month return-23.9%-2.0%2nd lowest of 21
6-month return-50.7%-9.7%lowest of 20
Distance from 52-week high-59.2%-30.2%3rd lowest of 21
Revenue growth (TTM)+26.3%-1.5%7th highest of 18
Operating margin17.8%4.5%3rd highest of 19
Forward P/E27.8×20.2×5th most expensive of 13
Growth the price implies (Req g, 7 yrs)4.2%2.9%4th most demanding of 9
Growth delivered (Del g)+21.7%+5.4%highest of 9
Hurdle (Req g minus delivered)-17.6 pp+4.8 ppleast demanding of 9
ROIC minus cost of capital+3.8 pp-3.8 pp4th highest of 19
EV / EBITDA13.2×14.9×3rd cheapest of 6
Net debt / EBITDA-0.8×-1.7×3rd most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%27.8×4.2%+21.7%
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%32.2×36.3%+20.4%
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%18.1×4.9%+11.3%
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%4.6×n/an/a
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%15.5×-3.6%+4.2%
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%418.7×n/an/a
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%n/an/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%18.4×3.4%-1.2%
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%14.5×n/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%n/a1.0%-4.2%
Omeros OMERUnited States$1.08B+24%n/a-56%4.3×n/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%22.1×-4.0%-9.0%
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%n/an/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%n/an/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%n/an/an/a
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%60.4×n/an/a

Questions

Which companies are ST Pharm's closest peers?
The cockpit's peer set: Viyash Scientific (VIYASH.NS), Symbiotec Pharmalab (SYMBIOTEC.NS), Tianjin Ringpu Bio-technology (300119.SZ), GC Biopharma (006280.KS), Vetoquinol (VETO.PA), Cosmo (CMHC.SW), PYC Therapeutics (PYC.AX), MedinCell (MEDCL.PA).
Is ST Pharm expensive compared with its peers?
On forward p/e it trades at 27.8× against a peer median of 20.2×, 5th most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -18 pp: the price already allows for a slowdown.
How has ST Pharm stock performed?
Over six months to 18 Nov 2026 the shares returned -50.7% against -9.7% for the median peer; over one year -29.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.